ClinicalTrials.gg
Sign In

Healthcare-Associated Pneumonia clinical trials

The registry lists 121 studies for Healthcare-Associated Pneumonia across more than 10 countries. 22 are recruiting or about to start. 48 of them are mainly about Healthcare-Associated Pneumonia (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30. Counting its narrower condition Pneumonia, Ventilator-Associated too: 488 studies, 96 open.

Get an email when these change. Save the Healthcare-Associated Pneumonia studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
70
Recruiting
16
Status unknown
12
Terminated
10
Not yet recruiting
5
Withdrawn
4

Phase

Phase 3
24
Phase 2
14
Phase 4
10
Phase 1
7

Where

United States
22
France
21
Spain
14
China
12
Brazil
10
Taiwan
9

Who runs them

Pfizer (11) · Tomsk National Research Medical Center of the Russian Academy of Sciences (5) · Nantes University Hospital (5) · Shionogi (3) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3) · Assiut University (3) · University Hospital Olomouc (3) · Assistance Publique - Hôpitaux de Paris (3)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 0 programmes from 0 companies, 0 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
MeropenemRecent, limited
Evidence
  • NCT06168734 · Venatorx Pharmaceuticals, Inc. · Phase 3 · comparator · “Meropenem” · registered Dec 2023
  • NCT03032380 · Shionogi · Phase 3 · comparator · “Meropenem” · registered Jan 2017
  • NCT02070757 · Merck & Co., Inc · Phase 3 · comparator · “Meropenem” · registered Feb 2014
Pfizer40% of its industry studiesUS: off-patent, 8 generics marketed11 study
VancomycinEarlier only
Evidence
  • NCT00543608 · Arpida AG · Phase 2 · comparator · “vancomycin” · registered Oct 2007
  • NCT00107952 · Cumberland Pharmaceuticals · Phase 3 · comparator · “Vancomycin” · registered Apr 2005
Pfizer27% of its industry studiesUS: off-patent, 32 generics marketed00 studies
LinezolidEarlier only
Evidence
  • NCT03032380 · Shionogi · Phase 3 · background · “Linezolid” · registered Jan 2017
  • NCT00229008 · basilea pharmaceutica · Phase 3 · comparator · “linezolid plus ceftazidime” · registered Sep 2005
Pfizer78% of its industry studiesUS: off-patent, 16 generics marketed00 studies

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 0 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorised original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Healthcare-Associated Pneumonia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Colistin112
Baricitinib111
Dexamethasone111
Amikacin101
Acyclovir111
Doripenem045
Nitric Oxide003
Cefiderocol023
Ceftolozane012
Chlorhexidine002

Drug classes tested here Corticosteroids 1 open · Beta-lactamase inhibitors 4

Coming up

3phase 3 studies under way
8studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 8, phase 3 first

Who these studies take

Of the 16 Healthcare-Associated Pneumonia studies recruiting now, 12 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (6%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (6%) take healthy volunteers.

Recruiting studies that take each age, of 16
AgeWomenMen
101 (6%)1 (6%)
1816 (100%)16 (100%)
3016 (100%)16 (100%)
4016 (100%)16 (100%)
5016 (100%)16 (100%)
6516 (100%)16 (100%)
7516 (100%)16 (100%)
8515 (94%)15 (94%)

Across all 121 studies, recruiting or not: 12% stop at 75 or younger and 9% at 65; 12% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Healthcare-Associated Pneumonia studies take

Of 23 interventional studies with no phase under Healthcare-Associated Pneumonia, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase24 mo8–42 · 23 studies——
Observational38 mo24–75 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 121. Browse all 121 → or search them.